Pan‐Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System

Pan‐Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare System

ABSTRACT Background The cumulative, health system‐wide survival benefit of immune checkpoint inhibitors (ICIs) is unclear, particularly among real‐world patients with limited life expectancies and among subgroups poorly represented on clinical trials. We sought to determine the health system‐wide su...

Full description

Bibliographic Details
Main Authors: Sean R. Miller, Matthew Schipper, Lars G. Fritsche, Ralph Jiang, Garth Strohbehn, Erkin Ötleş, Benjamin H. McMahon, Silvia Crivelli, Rafael Zamora‐Resendiz, Nithya Ramnath, Shinjae Yoo, Xin Dai, Kamya Sankar, Donna M. Edwards, Steven G. Allen, Michael D. Green, Alex K. Bryant
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Cancer Medicine
Subjects:
check point control
clinical cancer research
clinical observations
immune checkpoint inhibitors
Online Access:https://doi.org/10.1002/cam4.70379

Internet

https://doi.org/10.1002/cam4.70379

Similar Items